A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma.

Around 10％-30％ of non-small cell lung cancer(NSCLC)patients harbored epidermal growth factor receptor(EGFR)mutations,with L858R and exon-19 deletions(19-Del)ac-counting for 90％of cases.EGFR tyrosine kinase inhibitors(TKIs)showed significant efficacy against common EGFR mutations.However,the therapeutic relevance of uncom-mon EGFR mutations remained insufficiently investigated.